Responding to surging demand in the metabolic disease space, we have launched 50 new GLP-1 receptor agonist analogs available for immediate dispatch in research and GMP grades. The new catalog includes Semaglutide, Tirzepatide, Liraglutide, and 47 novel analogs with purity ≥98% guaranteed by RP-HPLC.
Responding to surging demand in the metabolic disease space, we have launched 50 new GLP-1 receptor agonist analogs available for immediate dispatch in research and GMP grades. The new catalog includes Semaglutide, Tirzepatide, Liraglutide, and 47 novel analogs with purity ≥98% guaranteed by RP-HPLC.
Our new 30,000 sq ft Phase III GMP synthesis suite has passed FDA pre-approval inspection, expanding our commercial-scale peptide API capacity by 60%. The suite features 4 new automated SPPS reactors and a dedicated lyophilization suite capable of processing 200L batches.
Hyxtide has entered a multi-year exclusive supply agreement for three oncology peptide APIs with a leading European pharmaceutical company, valued at over $45M. The agreement covers GMP-grade supply of three proprietary peptide APIs for Phase III clinical trials and commercial launch.
Hyxtide successfully completed its annual ICH Q7 third-party compliance audit with zero critical findings and only two minor observations, both resolved within 30 days. The audit covered all 8 synthesis suites, the analytical QC laboratory, and the cold-chain logistics center.
The global GLP-1 receptor agonist market is projected to exceed $100 billion by 2030, driven by obesity and type 2 diabetes treatment demand. As a leading GLP-1 peptide manufacturer, Hyxtide is positioned to support the growing need for high-purity GLP-1 APIs and analogs.
Our R&D team has published a peer-reviewed paper in the Journal of Peptide Science describing our proprietary continuous-flow synthesis platform, which reduces synthesis time by 40% and improves yield for complex long-chain peptides (>40 amino acids). The platform is now available for custom synthesis projects.
Hyxtide has expanded its cosmetic peptide portfolio with 15 new active ingredients targeting anti-aging, skin brightening, and hair growth applications. All products are available in cosmetic-grade (≥95%) and are REACH-compliant for EU market entry.
Hyxtide has been ranked #3 globally in the annual Peptide Science & Technology CRO/CMO survey, up from #7 in 2024. The ranking evaluates quality systems, delivery reliability, technical capability, and customer satisfaction across 200+ respondents from pharma and biotech companies.
The FDA has released updated guidance on peptide API manufacturing under 21 CFR Part 211, with new requirements for impurity profiling and process validation. Hyxtide's QA team has reviewed the guidance and confirmed full compliance. We summarize the key changes and their impact on peptide manufacturers.
Hyxtide has signed distribution agreements with two leading life science distributors in Japan and South Korea, expanding our Asia-Pacific presence. The partnerships will provide local regulatory support, warehousing, and customer service for research and pharmaceutical customers in both markets.
Hyxtide has entered a 3-year research collaboration with MIT's Department of Biological Engineering to develop novel peptide-lipid nanoparticle delivery systems for oral and transdermal administration. The collaboration is funded by a $2.5M NIH grant.
Hyxtide has successfully renewed its EU GMP certificate with an extended scope that now includes sterile fill-finish operations for injectable peptide formulations. The renewal follows a successful EMA inspection with no critical findings.
